Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion type Assertion NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_head.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion description "[These data showed that administration of the dual JAK1/2 inhibitor INCB16562 reduces malignant cell burden, normalizes spleen size and architecture, suppresses inflammatory cytokines, improves weight gain, and extends survival in a rodent model of JAK2V617F-driven hematologic malignancy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_provenance.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion evidence source_evidence_literature NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_provenance.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion SIO_000772 19887489 NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_provenance.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion wasDerivedFrom befree-20140225 NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_provenance.
- NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_assertion wasGeneratedBy ECO_0000203 NP802259.RAx2JfPjpRHtCbMi-ncz1vhPSc254hvFgcGzQVvJpbFKE130_provenance.